Research & Regulatory News

A Nationwide Cohort, and a Result That Points Away From the Drug

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Hviid and colleagues examined periconceptional GLP-1 receptor agonist exposure and obstetric outcomes across Danish health registries from October 2009 to December 2023, published in Human Reproduction Open in 2026. Preterm birth risk was raised where the medicines were used for diabetes but not for weight management.

Key facts

Study
Hviid 2026 (PMID 41852577)
Journal
Hum Reprod Open
Design
Nationwide observational cohort
Data source
Danish health registries
Period
October 2009 - December 2023
Liraglutide, diabetes
Preterm birth aOR 1.70 (1.17-2.48)
Semaglutide, diabetes
Preterm birth aOR 1.84 (1.24-2.7)
Weight management
Association not seen

Why Danish registries suit this question

They link prescribing, diagnoses and outcomes across an entire population with very little loss to follow-up. Pregnancy outcomes in people exposed to a specific medicine around conception is a question requiring both completeness and scale, and no trial would ever be conducted to answer it. Exposure in pregnancy is not something anyone randomises.

What was found

Increased preterm birth risk among those using the medicines for diabetes: liraglutide adjusted odds ratio 1.70 with a 95% confidence interval of 1.17 to 2.48, and semaglutide 1.84 with an interval of 1.24 to 2.7. Among those using them for weight management, the association was not present.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why the split is the actual result

Same medicines, same registry, same outcome, same period. The distinguishing feature between the two groups is the condition that prompted prescribing. A drug effect should not depend on why the drug was given, so the pattern points to the underlying diabetes rather than the medication, which the authors state as their own interpretation.

Why diabetes is a plausible cause here

Diabetes in pregnancy is an established risk factor for preterm birth through mechanisms long documented and independent of any modern medicine. An association appearing only where diabetes is present is consistent with the condition doing what it has always been known to do.

What the background section establishes about scale

The paper notes these agents are rapidly expanding among reproductive-age women, that they are not approved for use in pregnancy, and that inadvertent periconceptional exposure occurs frequently. It also notes that small studies have suggested no increased risk of major congenital malformations while comprehensive obstetric outcome data remained lacking. That is the gap this study addresses.

The limits

It is observational. Confounding by indication is what the design illuminates rather than something it wholly escapes, and residual confounding within each indication group remains possible. It reports obstetric outcomes rather than long-term outcomes for children, which is a separate question requiring longer follow-up.

The boundary

These are licensed medicines, not approved for use in pregnancy, prescribed and monitored clinically. Nothing supplied on this site is any of them, and nothing here is advice. Reproductive decisions belong with a clinician.

Frequently asked questions

Did the study find GLP-1 drugs cause preterm birth?

No. Raised risk appeared only where the medicines were used for diabetes, not for weight management, pointing to the underlying condition rather than the drug.

Why does the indication split matter so much?

A drug effect should not depend on why the drug was prescribed. That it did is evidence the association tracks the diabetes.

What are the study's limits?

It is observational, residual confounding within groups remains possible, and it reports obstetric outcomes rather than longer-term outcomes for children.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.